arrow
T

Timothy A. Graubert

Harvard Medical School
H指数:61
被引数:2.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity

唾液酸化的CD43形成一种糖免疫屏障,该屏障可抑制抗白血病免疫。

Science
IF45.8
2026-04-090
PRE
OGFOD1 enables AML chemo- and nutrient stress resistance by regulating protein synthesis

OGFOD1通过调控蛋白质合成使急性髓系白血病(AML)具有化疗和营养应激抗性。

2025-09-160
PRE
Integrative cytogenetic and molecular studies unmask chromosomal mimicry in hematologic malignancies

整合细胞遗传学和分子学研究揭示了血液系统恶性肿瘤中的染色体拟态现象

2025-03-111
OA
TRK Protein Expression in TP53 Altered Acute Erythroid Leukemia

TRK蛋白在TP53改变的急性红系白血病中的表达

BLOOD
IF23.1
2024-11-050
PRE
R-Loop Accumulation in Spliceosome Mutant Leukemias Confers Sensitivity to PARP1 Inhibition by Triggering Transcription-Replication Conflicts
2023-11-156
OA
PARP inhibitors preferentially sensitize splicing factor mutant myeloid neoplasms
2023-04-040
PRE
Long: molecular tracking of CML with bilineal inv(16) myeloid and del(9) lymphoid blast crisis and durable response to CD19-directed CAR-T therapy
LEUKEMIA
IF13.4
2020-07-163
PREAI
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial
2020-02-0126
OAAI
A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia
CANCER
IF5.1
2019-12-2016
OAAI
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
LEUKEMIA
IF13.4
2019-01-11177
OAAI
Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia
CANCER
IF5.1
2018-11-1326
OAAI
Mutation Clearance after Transplantation for Myelodysplastic Syndrome
2018-09-1398
OAAI
Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential
2018-01-31155
OAAI